<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03365687</url>
  </required_header>
  <id_info>
    <org_study_id>MP-21-2018-1657</org_study_id>
    <nct_id>NCT03365687</nct_id>
  </id_info>
  <brief_title>Vitamin D In the Prevention of Viral-induced Asthma in Preschoolers</brief_title>
  <acronym>DIVA</acronym>
  <official_title>Vitamin D In the Prevention of Viral-induced Asthma in Preschoolers: a Randomized Controlled Multicenter Trial (DIVA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professor Francine Ducharme</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EURO-PHARM International Canada, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this 7-month randomized controlled trial, children aged 1 to less than 6 years, with&#xD;
      recurrent asthma attacks triggered mostly by colds, will receive a high dose of vitamin D or&#xD;
      a placebo every 3.5 months during their usual clinic visit, and a daily supplement of vitamin&#xD;
      D or a placebo. This study will test whether children in vitamin D group have less frequent&#xD;
      and less severe asthma exacerbations compared with those receiving placebo.The study will&#xD;
      also document the safety profile of this strategy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter triple-blind randomized parallel-group, placebo-controlled trial of&#xD;
      vitamin D3 supplementation. Children aged 1-5 (&lt;6) years with physician-diagnosed asthma&#xD;
      predominantly triggered by upper respiratory tract infection will be screened for enrolment&#xD;
      in paediatric asthma, respiratory or allergy clinics and the ED departments and randomized&#xD;
      between Sept 1 to January 31, annually (4 recruitment years).&#xD;
&#xD;
      Using a computer-generated random list, stratified by site, children will be allocated (1:1)&#xD;
      using permuted block randomisation method to enhance concealment.&#xD;
&#xD;
      Children will be followed for 7 months, with 3 visits every 3.5 months with repeated urine&#xD;
      (for calcium:creatinine ratio) and blood samples. In addition, ten (10) days after each&#xD;
      bolus, urine will be sampled for urinary calcium:creatinine ratio. In case of elevated urine&#xD;
      calcium:creatinine ratio, a blood sample may be needed primarily for markers of calcium&#xD;
      metabolism and exploratory outcomes. Only patients enrolled at CHU Sainte-Justine and&#xD;
      Montreal Children's Hospital will receive a systematic home visit 10 days after first bolus&#xD;
      for both urine and blood samples. There will be 6 follow-up phone calls, at week 1 and then&#xD;
      monthly, to inquire about exacerbations and URTIs, remind parents to complete questionnaires&#xD;
      and to collect a nasal swab at each exacerbation and screen for adverse events.&#xD;
&#xD;
      The main outcome is the number of courses of rescue oral corticosteroids (OCS) per child&#xD;
      during the study period. Several secondary outcomes will be documented using biological&#xD;
      samples and validated questionnaires to ascertain laboratory-confirmed respiratory&#xD;
      infections, intensity and severity of exacerbations, mean number of ED visits, parents'&#xD;
      functional status during exacerbations, de-intensification of preventive asthma therapy, cost&#xD;
      effectiveness, and safety profile.&#xD;
&#xD;
      A sample of 432 children (400+7,5% attrition) per arm will provide 80% power with a&#xD;
      two-tailed alpha of 5% to detect a 25% relative reduction in the mean number of exacerbations&#xD;
      requiring OCS per child.&#xD;
&#xD;
      An intention-to-treat (ITT) analysis will be carried out with all randomised children.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomised, triple-blind, placebo-controlled, parallel-group multicentre trial of vitamin D3 supplementation.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The manufacturer, Europharm, will provide the active vitamin D3 and placebo preparations, identical in appearance and taste, in coded latex-free bottles. A web-based randomisation system will allow Site pharmacies to obtain allocated treatment number, prepare the 2 mL bolus in coded syringes and the coded bottles containing the daily dose, and dispense study drugs in masked kits.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of asthma exacerbations per child treated with rescue oral corticosteroids</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the mean number of exacerbations treated with rescue oral corticosteroids/child</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory-confirmed respiratory infections</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in mean number of laboratory-confirmed respiratory infections during asthma exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of asthma symptoms during asthma exacerbations</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the mean severity of asthma symptoms documented on the 'Asthma Flare-up Diary for Young Children'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of asthma symptoms during asthma exacerbations</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the mean duration of asthma symptoms documented on the validated 'Asthma Flare-up Diary for Young Children'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of use of rescue β2-agonists during asthma exacerbations</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the mean cumulative use of rescue β2-agonists during exacerbations documented on the validated 'Asthma Flare-up Diary for Young Children'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parents' functional status during asthma exacerbations</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the mean parents' functional status during exacerbation as documented on the validated 'Effect of a child's asthma flare-up on parents questionnaire'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of ED visits for asthma exacerbations</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in mean number of ED visits for asthma exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>De-intensification of preventive asthma therapy</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in proportion of children with de-intensification of preventive asthma therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention cost-effectiveness</measure>
    <time_frame>7 months</time_frame>
    <description>Cost of intervention vs. cost (family expenses and health care) of exacerbations</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hypercalciuria</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the proportion of children with ≥1 occurrence of hypercalciuria (urinary calcium: creatinine ratio &gt;1.38 mmol/mmol for children aged 1-&lt;2 years, or &gt;1.1 mmol/mmol for children aged 2-&lt;5 years, or &gt;0.77 mmol/mmol for children aged ≥5 years)</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypercalcemia</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the proportion of children with clinically significant hypercalcemia (&gt;2.63 mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Elevated serum 25-hydroxyvitamin D</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the proportion of children with ≥1 occurrence of elevated serum 25OHD (greater than 250 nmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Health Events</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the distribution of adverse health events</description>
  </other_outcome>
  <other_outcome>
    <measure>Gene expression</measure>
    <time_frame>3.5 months</time_frame>
    <description>Group difference in the change in gene expression levels (between baseline and 3.5 months) in blood peripherical mononuclear cells, adjusted for cell distribution estimated from lymphocyte differentiation in a subset of patients</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">865</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D supplement (100,000 IU) orally at baseline and at 3.5 months with daily 400 IU vitamin D for 7 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally at baseline and at 3.5 months with daily placebo during 7 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>2 mL of 50,000 IU/mL at baseline and at 3.5 months with a daily dose of 1 mL (400 IU/mL) for 7 months</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 mL of placebo at baseline and at 3.5 months with a daily dose of placebo (1 mL) for 7 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 1-5 years&#xD;
&#xD;
          -  Physician-diagnosed asthma (as per the 2015 Canadian Position Paper on the diagnosis&#xD;
             of preschool asthma)&#xD;
&#xD;
          -  ≥1 asthma exacerbation requiring rescue oral corticosteroids (OCS) in the past 6&#xD;
             months or ≥2 in the past 12 months (as documented by pharmacy/medical records)&#xD;
&#xD;
          -  ≥4 upper respiratory tract infections (URTIs) in the past 12 months (as per parental&#xD;
             report)&#xD;
&#xD;
          -  URTIs as the main asthma trigger (as per parental report)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intake &gt; 400 IU/day of vitamin D3 supplements or fish oil in the past 3 months&#xD;
&#xD;
          -  Intention to use &gt; 400 IU/day of vitamin D3 supplements or fish oil in the fall and&#xD;
             winter&#xD;
&#xD;
          -  Extreme prematurity (&lt; 28 week gestation)&#xD;
&#xD;
          -  No vitamin D supplementation (if breast-fed in the last 6 months)&#xD;
&#xD;
          -  Vitamin D restrictive diets, that is, minimal intake of vitamin D fortified milk (&lt;250&#xD;
             mL/day for 1-3 years or &lt;375 mL/day for 4-6 years AND no other (or &lt;200 IU/day)&#xD;
             vitamin D supplement&#xD;
&#xD;
          -  Recent immigrants from regions at high risk of rickets (in the past 12 months)&#xD;
&#xD;
          -  Recent refugees (in the past 12 months)&#xD;
&#xD;
          -  Undernourished children&#xD;
&#xD;
          -  Other chronic respiratory disease (e.g. Cystic fibrosis, Bronchopulmonary dysplasia)&#xD;
             or chronic kidney, gastrointestinal, endocrinological or cardiac diseases, or sickle&#xD;
             cell anemia?&#xD;
&#xD;
          -  History of bone disorder disease (e.g. rickets, osteomalacia)&#xD;
&#xD;
          -  Intake of oral anti-epileptic, diuretic or anti-fungal medications&#xD;
&#xD;
          -  Anticipated difficulty with follow-up or with adherence to the intervention or the&#xD;
             procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francine M Ducharme, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francine M Ducharme, MD</last_name>
    <phone>514-345-4931</phone>
    <phone_ext>4398</phone_ext>
    <email>francine.m.ducharme@umontreal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amina Hasanova, MSc</last_name>
    <phone>514-345-4931</phone>
    <phone_ext>2157</phone_ext>
    <email>amina.hasanova@recherche-ste-justine.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Yang, MD</last_name>
      <phone>1-6048752000</phone>
      <phone_ext>4931</phone_ext>
      <email>connie.yang@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Connie Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 2V5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Bock, MD</last_name>
      <phone>1-5196858824</phone>
      <email>Dirk.Bock@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Dirk Bock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dhenuka Radhakrishnan, MD</last_name>
      <phone>1-6137377600</phone>
      <phone_ext>2868</phone_ext>
      <email>dradhakrishnan@cheo.on.ca</email>
    </contact>
    <investigator>
      <last_name>Dhenuka Radhakrishnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Alizadehfar, MD</last_name>
      <email>reza.alizadehfar@muhc.mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Duncan Lejtenyi, MSc</last_name>
      <phone>1-514-412-4400</phone>
      <phone_ext>22369</phone_ext>
      <email>duncan.lejtenyi@muhc.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Reza Alizadehfar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sze Man Tse</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>54</phone_ext>
      <email>sze.man.tse@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Sze Man Tse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc-Andre Turcot, MD</last_name>
      <email>marc-andre.turcot@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Marc-Andre Turcot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Québec-Université Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Daigneault, MD</last_name>
      <email>Patrick.Daigneault@mail.chuq.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Louise Gosselin</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>48290</phone_ext>
      <email>louise.gosselin@chudequebec.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Daigneault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Jensen ME, Ducharme FM, Alos N, Mailhot G, Mâsse B, White JH, Sadatsafavi M, Khamessan A, Tse SM, Alizadehfar R, Bock DE, Daigneault P, Lemire C, Yang C, Radhakrishnan D. Vitamin D in the prevention of exacerbations of asthma in preschoolers (DIVA): protocol for a multicentre randomised placebo-controlled triple-blind trial. BMJ Open. 2019 Dec 30;9(12):e033075. doi: 10.1136/bmjopen-2019-033075.</citation>
    <PMID>31892662</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 3, 2017</study_first_submitted>
  <study_first_submitted_qc>December 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <last_update_submitted>September 27, 2020</last_update_submitted>
  <last_update_submitted_qc>September 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Professor Francine Ducharme</investigator_full_name>
    <investigator_title>Pediatrician</investigator_title>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Respiratory viral infection</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Asthma exacerbations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

